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Abstract
Objective. The aim of this study was to assess the prognostic value of systolic pulmonary artery pressure
(sPAP) estimated by echocardiography in the multinational European League Against Rheumatism
Scleroderma Trial and Research (EUSTAR) cohort.
Methods. Data for patients with echocardiography documented between 1 January 2005 and 31
December 2011 were extracted from the EUSTAR database. Stepwise forward multivariable statistical
Cox pulmonary hypertension analysis was used to examine the independent effect on survival of selected
variables.
Results. Based on our selection criteria, 1476 patients were included in the analysis; 87% of patients
were female, with a mean age of 56.3 years (S.D. 13.5) and 31% had diffuse SSc. The mean duration of
follow-up was 2.0 years (S.D. 1.2, median 1.9). Taking index sPAP of <30 mmHg as reference, the hazard
ratio (HR) for death was 1.67 (95% CI 0.92, 2.96) if the index sPAP was between 30 and 36 mmHg, 2.37
(95% CI 1.14, 4.93) for sPAP between 36 and 40 mmHg, 3.72 (95% CI 1.61, 8.60) for sPAP between
40 and 50 mmHg and 9.75 (95% CI 4.98, 19.09) if sPAP was >50 mmHg. In a multivariable Cox
model, sPAP and the diffusing capacity for carbon monoxide (DLCO) were independently associated
with the risk of death [HR 1.833 (95% CI 1.035, 3.247) and HR 0.973 (95% CI 0.955, 0.991), respectively].
sPAP was an independent risk factor for death with a HR of 3.02 (95% CI 1.91, 4.78) for sPAP
536 mmHg.
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Conclusion. An estimated sPAP >36 mmHg at baseline echocardiography was significantly and inde-
pendently associated with reduced survival, regardless of the presence of pulmonary hypertension based
on right heart catheterization.
Key words: systemic sclerosis, tricuspid regurgitant jet velocity, systolic pulmonary arterial pressure, pulmonary
hypertension, survival.
Rheumatology key messages
. The hazard ratio for death was 3.02 (95% CI 1.91, 4.78) for systolic pulmonary artery pressure 5 36 mmHg in
SSc patients.
. The hazard ratio for death was 4.94 (95% CI 2.66, 9.17) for DLCO <64% of predicted in SSc patients.
. Right heart catheterization should be considered each time pulmonary hypertension is suspected in SSc
patients.
Introduction
Pulmonary arterial hypertension (PAH) is a frequent com-
plication of SSc with a prevalence 10% [1, 2]. Right
heart catheterization (RHC) is mandatory for the diagnosis
of PAH. Pulmonary hypertension (PH) is defined on RHC
by a mean pulmonary artery pressure (mPAP) of
525 mmHg at rest with a mean pulmonary arterial
wedge pressure (mPAWP) of <15 mmHg [3]. Within the
last two decades, interstitial lung disease (ILD) and PAH
have become the leading causes of death in SSc patients
[4, 5]. The estimated 3 year survival among patients with
PAH associated with SSc without therapy is 5060%
[69] and is worse than the prognosis observed in idio-
pathic PAH. Many factors can explain this dismal progno-
sis. Among them, older age, cardiomyopathy and the high
prevalence of pulmonary veno-occlusive disease have
been proposed. Moreover, PAH is often diagnosed in an
advanced stage in SSc, with up to 75% of patients being
in New York Heart Association functional class III or IV. To
improve this prognosis, and taking the high prevalence of
PAH into account, yearly screening for PAH in SSc pa-
tients is suggested by various guidelines [10]. Thus far,
echocardiography is the most used screening tool for sus-
pect PH in SSc. Based on the tricuspid regurgitant jet
(TRJ) velocity, estimated systolic pulmonary artery pres-
sure (sPAP) can be calculated using the Bernoulli equation
and adding estimated right atrial pressure (RAP). The
European Society of Cardiology/European Respiratory
Society (ESC/ERS) diagnostic algorithm in SSc patients
with suspected PH is based on the maximal TRJ [3]: a
patient with a TRJ of 42.8 m/s (estimated sPAP
436 mmHg, assuming mean RAP (mRAP) 45 mmHg) is
unlikely to have PH. Based on this algorithm, RHC should
be considered in SSc patients with suspected PH if the
TRJ is between 2.9 and 3.4 m/s (corresponding to an es-
timate sPAP of between 37 and 50 mmHg, assuming RAP
is 5 mmHg) in symptomatic patients and if the TRJ is
>3.4 m/s (corresponding to an estimate sPAP
>50 mmHg, assuming RAP is 5 mmHg) in non-symptom-
atic patients. We have previously shown in a large nation-
wide prospective study that if RHC is performed in the
case of a TRJ >2.8 m/s, it is possible to identify at an
early stage SSc patients suffering from PAH and survival
can be improved with early therapeutic intervention
[10, 11]. In the trans-sectional study performed initially,
we used a TRJ cut-off of 2.5 m/s, which seemed too low
to identify SSc patients at risk of PH and produced a rela-
tively high percentage of false-positive results [12].
Unfortunately, in real practice, RHC is not systematically
performed in all SSc patients in whom PH is suspected.
Therefore, while the prognosis of RHC-proven PAH is
known, there are no data on the prognostic value of esti-
mate sPAP, regardless of the presence of RCH-proven
PH, whatever the mechanism of PH. Thus the aim of the
present study was to assess the prognostic value of sPAP
estimated from the TRJ measured by echocardiography
to predict 5 year survival in patients with SSc using the
multinational European League Against Rheumatism
Scleroderma Trial and Research (EUSTAR) cohort.
Methods
Data collection
Population
From June 2004 onwards, EUSTAR centres were re-
quested to enter patient data into a web database, pro-
vided that the patients had given their informed written
consent. Data were to be collected at each visit and at
least once a year. Since the aim of our study was to evalu-
ate the prognostic value of estimated sPAP in the modern
PAH therapeutic era, data collected from 2005 to 31
December 2011 were extracted from the EUSTAR data-
base. The database started in 2004, but information about
sPAP was requested from 2007 with the development of
the online database. It was also possible from 2007 to
enter patients with a record of previous echocardiogra-
phies performed before 2007. Patients were selected if
they had a first echocardiography after 1 January 2005
with at least one follow-up visit between the 1 January
2005 and the 31 December 2011. The first echocardiog-
raphy performed after 1 January 2005 with an evaluation
of sPAP was termed the index echocardiography. Data of
all subsequent visits were used provided that at least
one echocardiography and/or RHC was performed.
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Patients with PH or PAH documented by a RHC before 1
January 2005 were also excluded from the study. The
EUSTAR scientific committee approved the evaluation of
the prognostic value of sPAP in patients suffering from
SSc included in the EUSTAR database. Ethics committee
approval for the study was obtained from each participat-
ing EUSTAR centre (based on Ethics Committee
Approval, Basel, Switzerland, no. 323/09).
Collected data
Collected data included demographics, history of RP, his-
tory of the first non-RP symptom of SSc, subtype of SSc
(diffuse, limited or other), modified Rodnan skin score
(mRSS), history of renal crisis, immunological status, dys-
pnoea level based on the NYHA classification, history of
digital ulcers, systemic treatments and co-morbidity with
systemic hypertension. Available data regarding echocar-
diography [TRJ, sPAP, left ventricular ejection fraction
(LVEF), diastolic dysfunction, pericardial effusion], RHC
(right ventricular systolic pressure, mPAP, pulmonary re-
sistance, PAWP, cardiac index), 6 min walking test (dis-
tance walked, oxygen saturation at rest and during
exercise), pulmonary function tests, diffusion capacity
for carbon monoxide (DLCO), forced vital capacity
(FVC), total lung capacity (TLC) and forced expiratory
volume in 1 s were collected at the date of the index
echocardiography. The different sPAP categories were
based on the 2009 ESC/ERS recommendations [3]: if
sPAP is <36 mmHg, PH is unlikely; if sPAP is
>36 mmHg but <50 mmHg, PH is possible and if sPAP
is >50 mmHg, PH is likely. A restrictive lung syndrome
was defined as a FVC or TLC <70% of predicted. If avail-
able, data regarding lung fibrosis from a high-resolution
CT scan were entered in the database.
Survival status of the patient was evaluated at the date
of the last available information. If the patient died during
the follow-up period, the date of death was provided by
the centre. We also asked all centres with at least one
patient meeting inclusion criteria whether RHC was per-
formed during follow-up and to provide the results, in case
the information was missing in the EUSTAR database. A
data review was conducted prior to analysis in order to
determine whether the patient could be included in the
analysis.
Data analysis
Results are expressed as mean (S.D.) for continuous vari-
ables and as n (%) for categorical variables. All-cause
mortality was used for analyses. The date of index echo-
cardiography was considered the baseline from which
survival was measured. Individual analyses based on the
Cox PH model were used to examine relationships be-
tween survival and selected variables measured at index
echocardiography. Events were right-censored at 5 years
of follow-up. Stepwise forward multivariable Cox PH ana-
lysis was used to examine the independent effect on sur-
vival of selected variables (those with a P-value40.20
from individual analysis with sufficient documentation),
controlling for possible confounders. Assumptions on
comparable characteristics of censored and uncensored
patients and were tested. The constancy of the HR over
time was evaluated. The DLCO threshold was derived
from logistic regression models and receiver operating
characteristic (ROC) curves. In addition, we performed re-
gression analysis using sPAP at the index echocardiog-
raphy as a continuous variable and we then conducted
multivariate analysis limited to sPAP and one of the
other potentially explanatory variables. We examined the
regression coefficient for each millimetre of mercury of
sPAP and considered that the other variable added infor-
mation if it led to a change in the sPAP regression coef-
ficient of at least 10%. Statistical analyses were
performed with SAS version 9.1 (SAS Institute, Cary,
NC, USA).
Results
Population characteristics
A total of 24 405 visits involving 9616 patients were ex-
tracted from the EUSTAR database. Among these pa-
tients, 420 had only one documented visit before 1
January 2005, 4789 had no documented sPAP at any
visit, 13 were <18 years old and 12 died at the first visit.
In addition, 404 did not meet the ACR criteria, 1965 had
their first visit before 1 January 2005 and 67 had a diag-
nosis of PAH before the first visit recorded in the data-
base. For the remaining 1946 patients, all centres were
contacted to obtain the survival status and to determine
if RHC was performed at any time during follow-up; we
received a response from the centres for 1476 patients.
Therefore 1476 patients from 54 centres were included in
the analysis.
The characteristics of the analysed patients at baseline
are summarized in Table 1. Mean duration of follow-up
was 2.0 years (S.D. 1.2, median 1.9). During this period
of follow-up, of the 273 patients who had an index sPAP
536 mmHg, 44 (16.1%) underwent RHC: 24 were found
to have PAH, 6 to have post-capillary PH and 4 to have PH
related to ILD. In total, 42 (2.8%) patients were diagnosed
with PAH during this period, whereas post-capillary PH
was found in 14 (0.9%) patients and PH related to ILD
was found in 6 (0.4%) patients.
Prognostic value of estimated sPAP at baseline and
other risk factors of death
During the follow-up period, 76 patients died (only 15
deaths were recorded to be related to SSc, but data
were missing). Whether death was related to PH was
not provided due to the structure of the database. The
overall 5 year survival rate was 79.7% (95% CI 72.6%-,
85.1%). KaplanMeier estimates of the survival distribu-
tion were significantly different across index sPAP values,
as shown in Fig. 1 (log-rank test P< 0.0001). The esti-
mated 5 year survival rate decreased from 88.2% (95%
CI 78.9%-, 93.5%) in patients with an index sPAP
<30 mmHg to 28.4% in patients with an index sPAP
550 mmHg. Assuming a sPAP threshold of 36 mmHg,
the estimated 5 year survival rate was 85.7% (95% CI
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78.5, 90.6) in patients with an sPAP <36 mmHg and
57.3% (95% CI 38.4%-, 72.3%) in patients with an
sPAP 536 mmHg. The 1, 2 and 3 year survival rates are
provided in Table 2.
Taking the index estimated sPAP <30 mmHg as refer-
ence, a Cox model showed that HRs for death were 1.67
(95% CI 0.94, 3.06) if the index sPAP was 530 and
<36 mmHg, 2.31 (95% CI 1.04, 5.12) for an sPAP 536
and <40 mmHg, 2.79 (95% CI 1.30, 5.97) for an sPAP
540 and <50 mmHg and 8.39 (95% CI 4.40, 16.17) if
the sPAP was 550. Taking the index estimated sPAP
<36 mmHg as a reference, SSc patients with an sPAP
536 mmHg had a poorer prognosis. Survival rates were
99.4% (95% CI 98.7%, 99.7%), 97.0% (95% CI 95.6%,
98.0%) and 93.8% (95% CI 91.1%, 95.7%) at the 1, 2 and
3 year follow-ups in patients with an index sPAP
<36 mmHg, compared with 98.0% (95% CI 95.3%,
99.2%), 92.5% (95% CI 87.5%, 95.5%) and 80.6%
(95% CI 71.3%, 87.2%) for patients with an index sPAP
536 mmHg. HR for death was 3.02 (95% CI 1.91, 4.78) for
PAPs 536 mmHg.
Finally, DLCO <60% was associated with a HR of 8.30
(95% CI 2.96, 23.25) for death vs DLCO 580%. Using
logistic regression modelling, the vital status of the patient
at the end of follow-up and plotting a ROC curve, we
found 64% of predicted DLCO to be the best cut-off
value. This threshold was associated with a HR of 4.94
(95% CI 2.66, 9.17) for death. The 3 year survival rate
was 77.5% (95% CI 63.6%-, 86.6%) if the DLCO was
<64% vs 88.4% (95% CI 62.9%-, 96.8%) if the DLCO
was 564%.
Besides the index sPAP and DLCO, numerous charac-
teristics of patients at the index visit were associated with
survival (Table 3). In a multivariate Cox model with step-
wise selection, DLCO, age, TLC and index sPAP were
independently associated with the risk of death: for each
point lost in the index DLCO (expressed as a percentage
of the theoretical value), the 5 year risk of death increased
by 2.7% (95% CI 0.9%-, 4.5%); for each year of age, the
risk increased by 6.5% (95% CI 3.9%-, 9.3%); for a loss of
1% of predicted TLC, the risk increased by 2.6% (95% CI
1.1%, 4.0%) and the risk was 1.83-fold greater (95% CI
1.035, 3.25) if the index sPAP was 536 mmHg (Table 4).
Other variables (i.e. gender, diffuse SSc, mRSS, LVEF,
diastolic dysfunction and pericardial effusion) were not
retained in the multivariate model. In addition, we per-
formed regression analysis using sPAP at the index echo-
cardiography as a continuous variable and then
conducted multivariate analysis limited to sPAP and one
of the other potentially explanatory variables. We exam-
ined the regression coefficient for each millimetre of mer-
cury of sPAP and considered that the other variable
added information if it led to a change in the sPAP regres-
sion coefficient of at least 10%. Only patient age and
DLCO at the index visit met this criterion.
Discussion
The international guidelines recommend echocardio-
graphic screening in SSc for the detection of PH in symp-
tomatic patients [World Health Organization (WHO) class
I, level B] [13] and may be considered in asymptomatic
patients (WHO class IIb, level C). Moreover, experts rec-
ommend that systematic screening of PH should be done
at least yearly in all SSc patients because it is the only way
to detect early PAH [11, 14], allowing early management
with better survival [15].
In the present study we have demonstrated that the
best cut-off for sPAP in terms of survival prognostic
factor is 36 mmHg (corresponding to a TRJ of 2.8 m/s,
assuming mRAP is 5 mmHg). sPAP was an independent
risk factor for death in patients with SSc who were not
known to be suffering from PH or PAH at the time of the
index echocardiography, with a HR of 3.02 (95% CI 1.91,
4.78) for sPAP 536 mmHg. In a smaller, single-centre
TABLE 1 Characteristics of the 1476 patients analysed
Total
number
documented Data
Female 1476 1280 (86.7)
BMI, kg/m2 742 24.4 (4.4)
Age, years 1476 56.3 (13.5)
Time since RP, years 1457 13.9 (11.1)
Time since non-RP first symptom,
years
1350 9.5 (7.6)
dcSSc 1476 462 (31.3)
lcSSc 1476 984 (66.7)
Limited SSc 1476 30 (2.0)
Modified Rodnan skin score 1298 8.9 (7.3)
Hypertension 1454 309 (21.3)
History of renal crisis 1384 20 (1.5)
Active digital ulcers 1457 520 (35.7)
Lung fibrosis (on HRCT) 862 439 (50.9)
Restrictive syndrome
(FVC and/or TLC <70%)
1402 332 (23.7)
ANAs 1392 1345 (96.6)
ACAs 1342 499 (37.2)
Anti-topoisomerase antibodies 1343 469 (34.9)
NYHA functional class 1379
I 771 (55.9)
II 474 (34.4)
III 116 (8.4)
IV 18 (1.3)
sPAP, mmHg 1476 29.8 (9.5)
DLCO, % 1340 68.7 (19.5)
FVC, % 1343 96.0 (21.7)
TLC, % 692 92.6 (19.4)
LVEF, % 1339 62.0 (5.9)
Diastolic dysfunction 1374 294 (21.4)
Pericardial effusion 1252 91 (7.3)
Results are the number of documented patients expressed
as the mean (S.D.) for continuous variables or as n (%) for
categorical variables. Percentages are calculated on the
number of documented variables. DLCO: diffusing capacity
for carbon monoxide; FVC: forced vital capacity; HRCT:
high-resolution computed tomography; LVEF: , left ventricu-
lar ejection fraction; NYHA: New York Heart Association;
sPAP: systolic pulmonary artery pressure; TLC: total lung
capacity.
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study (n= 115), Kiatchoosakun et al. [16] showed that
sPAP was independently associated with decreased sur-
vival, with a 3 year survival rate of 67%, which is very
close to the present analysis.
While it was interesting to demonstrate that sPAP is an
independent risk factor for death, irrespective of the pres-
ence of PH, and irrespective of the patient’s status and
the final diagnosis, the fact that 16.1% of patients with
sPAP >36 mmHg (corresponding to a TRJ >2.8 m/s,
assuming the mRAP is 5 mmHg) at the index echocardi-
ography never underwent RHC over the follow-up period
is surprising (each centre was individually contacted to
determine whether, from the date of the index echocardi-
ography to 31 December 2011, patients underwent RHC
and, if yes, what was the result). Indeed, as a patient with
a TRJ >3.4 m/s (or sPAP >50 mmHg) is likely to have PH,
RHC is indicated to confirm the diagnosis according to
ESC/ERS recommendations [3]. It seems likely that some-
times poor access to RHC and the fear of asking for RHC
may contribute to this low number of patients with a clear
indication for RHC but with no RHC performed. As a limi-
tation, we know that echocardiography has some weak-
ness in identifying SSc patients at risk of PH. Notably, TRJ
of measurable quality was 8186% when the Doppler
evaluation was performed by a highly experienced echo-
cardiographer [12, 17]. We previously found that in SSc
patients with TRJ >2.5 m/s, 55% had PAH on RHC, an-
other 10% had post-capillary PH and 18% had borderline
mPAP (between 21 and 24 mmHg) [12]. Moreover,
Coghlan et al. [18] recently showed that 20% of SSc pa-
tients with PAH had TRJ 42.5 m/s and 36% had TRJ
42.8 m/s.
FIG. 1 Five-year survival distribution function according to sPAP at index echocardiography
Dashed line: sPAP <36 mmHg; solid line: sPAP 536 mmHg (values at index echocardiography). sPAP: systolic pul-
monary arterial pressure.
TABLE 2 Risk of death associated with sPAP at index echocardiography
sPAP <36mmHg
(n=1203)
36 4 sPAP 4 50mmHg
(n=213)
sPAP >50mmHg
(n=48)
1 year survival estimate, % (95% CI) 99.4 (98.7, 99.7) 98.9 (95.8, 99.7) 93.4 (81.0, 97.8)
2 year survival estimate, % (95% CI) 97.0 (95.6, 98.0) 93.5 (87.8, 96.6) 86.5 (69.7, 92.0)
3 year survival estimate, % (95% CI) 93.8 (91.1, 95.7) 84.5 (73.7, 91.2) 66.5 (42.8, 82.1)
Hazard ratio (95% CI) 1.44 (1.06, 1.96) 1.83 (1.43, 2.33)
Data are right-censored at 60 months. hazard ratios are derived from a Cox model. The 1, 2 and 3 year survival rates were
estimated with a KaplanMeier model. sPAP: systolic pulmonary arterial pressure.
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Based on the EUSTAR database, Tyndall et al. [5] found
that suspected PH based on echocardiography was an
independent risk factor of death. In the study performed
by Fransen et al. [19], which was also based on the
EUSTAR database, age, ESR and DLCO <70% of pre-
dicted were independent factors of death, with an OR of
1.94 for DLCO <70%. Our results suggest that while these
three disease factors may predict 5 year survival at SSc
diagnosis, sPAP (and TRJ) should now also be considered
as another independent survival prognostic factor.
As reported by Steen et al. [20], DLCO may be signifi-
cantly decreased (i.e. <60% of normal) for many years
prior to the occurrence of PAH. In the DETECT study
[18], among SSc patients with >3 years of evolution and
a DLCO <60% of predicted without severe ILD or severe
known left heart disease, it was shown that of 466 patients
who underwent RHC, 31% (n= 144) had PH, 19% (n= 87)
had PAH, 6% (n= 30) had post-capillary PH and 6%
(n= 27) had PH associated with ILD. In the present study
we have demonstrated that a DLCO <64%, independent
of pulmonary or cardiac status, is an independent risk
factor for death in SSc. An index DLCO of <64% was
also associated with a 4.87-fold risk of death (95% CI
1.3, 17.6). From the DETECT study, we know that 31%
of SSc patients with a DLCO <60% of predicted have PH.
Consequently we should consider that all SSc patients
with a sPAP >36 mmHg (corresponding to a TRJ
>2.8 m/s, assuming mRAP is 5 mmHg) and/or a DLCO
<64% are at a high risk of PH and subsequently of
death. These patients should be monitored carefully and
the question of performing RHC should be discussed on a
regular basis. As 50% of the patients in the EUSTAR
database had no documented sPAP, we recommend
that regular echocardiography screening should be per-
formed. Moreover, since 83.6% of the patients who had
sPAP >36 mmHg (corresponding to TRJ >2.8 m/s,
assuming mRAP is 5 mmHg) never underwent RHC
during the follow-up period, this should be considered a
red flag pointing to a life-threatening situation that needs
to be investigated. In such cases, RHC is mandatory to
confirm or exclude PH and to clearly categorize the mech-
anism of PH.
There are some strengths and limitations of our study.
The strengths are the large number of patients analysed,
TABLE 3 Patient characteristics at the index visit associated with risk of death (univariate analysis)
Parameter S.E. HR (95% CI) P-value
Age, years 0.05 0.01 1.05 (1.03, 1.08) <0.0001
Male 0.75 0.26 2.13 (1.28, 3.55) 0.004
Diffuse SSc 0.63 0.23 1.87 (1.19, 2.95) 0.007
sPAP, mmHg 0.05 0.007 1.06 (1.04, 1.07) <0.0001
DLCO, % 0.05 0.008 0.95 (0.94, 0.97) <0.0001
FVC, % 0.04 0.006 0.97 (0.95, 0.98) <0.0001
TLC, % 0.04 0.009 0.96 (0.95, 0.98) <0.0001
mRSS, per unit 0.04 0.01 1.04 (1.01, 1.07) 0.005
LVEF, % 0.05 0.02 0.95 (0.92, 0.98) 0.003
Diastolic dysfunction 0.40 0.26 1.50 (0.89, 2.51) 0.13
Pericardial effusion 0.83 0.36 2.29 (1.13, 4.63) 0.02
Lung fibrosis 0.47 0.28 1.60 (0.92, 2.77) 0.10
PAH or PH 1.49 0.27 4.43 (2.63, 7.48) <0.0001
DLCO, FVC and TLC are expressed as a percentage of the theoretical value. DLCO: diffusion capacity for
carbon monoxide; FVC: forced vital capacity; HR: hazard ratio; LVEF: left ventricular ejection fraction;
mRSS: modified Rodnan skin score; PAH: pulmonary arterial hypertension; PH: pulmonary hypertension;
sPAP: systolic pulmonary arterial pressure; TLC: total lung capacity.
TABLE 4 Patient characteristics at the index visit associated with risk of death (multivariate analysis)
Parameter S.E. HR (95% CI) P-value
DLCO, % predicted 0.02765 0.00939 0.973 (0.955, 0.991) 0.003
Age, year 0.06330 0.01296 1.065 (1.039, 1.093) <0.0001
TLC, % predicted 0.02638 0.00763 0.974 (0.960, 0.989) 0.0005
sPAP 536 mmHg 0.60604 0.29161 1.833 (1.035, 3.247) 0.04
DLCO and TLC are expressed as a percentage of the theoretical value. DLCO: diffusion capacity for
carbon monoxide; HR: hazard ratio; sPAP: systolic pulmonary arterial pressure; TLC: total lung capacity.
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the real-life conditions and the confirmation of data re-
garding survival status by each centre for all analysed pa-
tients. In contrast, the key limitations of our (real-life) study
are that patients were selected on available sPAP. This
may have induced a selection bias towards patients ex-
hibiting symptoms, thus impairing inference to the whole
population of SSc patients. Selection bias is more likely at
earlier times, where regular screening assessment was
not the rule, but is less likely after the recommendations
regarding regular echocardiographic screening for PAH
were published. There are some missing data (e.g. the 6
min walking test was documented in only 268 patients and
could not be used for the multivariate analysis) and indi-
vidual practices in each centre varied regarding the deci-
sion to perform RHC in patients with sPAP 536 mmHg,
which certainly impacted the delay of PH diagnosis. In
addition, because the centre did not answer our query,
we were able to analyse only 1476 patients of 1946 meet-
ing the inclusion criteria.
In conclusion, our data support the idea that in routine
clinical management of SSc patients, sPAP 536 mmHg
should be seen as a red flag indicating a high risk of
death, resulting in immediate RHC to identify or exclude
PH.
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